Exact Sciences Corp
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
548 / 1361
Position in country
8646 / 14179
Return on Assets, %
-3.3
-40.3
Net income margin, %
-7.7
-180
EBITDA margin, %
-2.2
-168.2
Debt to Equity, %
75.7
3.2
Intangible assets and goodwill, %
65.7
0.2
Revenue CAGR 3Y, %
18.7
12.5
Total Equity change 1Y, %
3.3
-9
Revenue Y, % chg
19.9
0
P/BV
4.1
1.8
P/S
5.1
10.3
EV/S
5.8
7.5
EV/EBITDA
-1925.4
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
24.2
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Exact Sciences Corp
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
12950.4
Ticker
EXAS.O
ISIN
US30063P1057
IPO date
2001-01-30
Availability on Russian exchanges
Yes
Reporting for
2024-02-21
Date fact. publication of reports
2023-12-31
Company Description
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: